Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Trump Says Anthropic No Longer Seen as National Security Threat 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Vital Therapies, Inc. (NASDAQ:VTL) securities from April 17, 2014 through August 21, 2015 all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Vital Therapies investors under the federal securities laws.
To join the Vital Therapies class action, go to the website at http://www.rosenlegal.com/cases-671.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose material information regarding Vital Therapies’ ELAD System studies, VTI-208, VTI-210, and VTI-212, including: (1) the studies’ independent significance; (2) the degree to which the studies were interrelated; and (3) that in the case of the failure of the VTI-208 trial, Vital Therapies would not continue the VTI-210 trial. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-671.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] www.rosenlegal.com
